글로벌 재발성 이하선염 치료 시장 – 2030년까지의 산업 동향 및 예측

재발성 이하선염 치료 시장 분석 및 규모

어린이의 재발성 이하선염 발생률은 더 흔하게 보고되며, 소아 인구에서 추정 발생률은 0.2%에서 5% 사이입니다. 남성에게 여성보다 더 흔하며, 이 질환은 종종 3세에서 5세 사이에 나타납니다. 성인의 경우 재발성 이하선염 발생률은 어린이에 비해 낮지만 여전히 발생할 수 있습니다.

Data Bridge Market Research는 2022년에 5,169.56백만 달러였던 재발성 글로벌 이하선염 치료 시장이 2030년까지 8,364.68백만 달러에 도달할 것으로 예상되며, 2023-2030년 예측 기간 동안 6.2%의 CAGR을 보일 것으로 예상된다고 분석했습니다. 이는 시장 가치를 나타냅니다. "외과적 절제"는 더 나은 치료 수술 방법에 대한 수요가 증가함에 따라 재발성 글로벌 이하선염 치료 시장의 치료 부문을 지배하고 있습니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

재발성 이하선염 치료 시장 범위 및 세분화

시장 정의

머리 양쪽의 귀와 턱 사이의 뺨에 위치한 타액선인 하나 또는 둘 다의 이하선이 붓는 것을 이하선염이라고 합니다. 재발성 이하선염은 일반적으로 비폐쇄성 이하선 침샘 확장증과 관련된 재발성 이하선 염증입니다. 소아의 재발성 이하선염은 청소년 재발성 이하선염이라고도 합니다. 이 질환은 발열과 불쾌감을 동반하는 경우가 많은 이하선의 붓기 및/또는 통증이 반복적으로 나타나는 것이 특징입니다. 일반적으로 청소년에게 영향을 미치지만 성인에게도 영향을 미칠 수 있습니다. 드문 질환이며 원인은 아직 알려지지 않았습니다. 타액의 과소 생산, 박테리아 또는 바이러스 감염의 병력, 타액관의 선천적 기형, 유전적 소인 또는 기저 자가면역 질환은 연구자들이 조사하고 있는 가능성 중 일부입니다. 이하선 부종은 타액의 정상적인 흐름이 중단되어 발생하는 것으로 보이며, 이로 인해 이하선이 감염됩니다.

글로벌 재발성 이하선염 치료 시장 역학

운전자

• 재발성 이하선염의 유병률 증가

인구 중 재발성 이하선염의 증가는 치료 시장 성장의 주요 원동력입니다. 더 많은 사람들이 이 질환으로 진단받으면서 효과적인 치료 옵션에 대한 수요가 증가합니다.

• 의료 기술의 발전

Technological advancements in diagnostic techniques and treatment modalities have improved the accuracy of diagnosis and enhanced the effectiveness of treatment. This has led to increased adoption of treatment options for recurrent Parotitis.

• Rising Demand for Minimally Invasive Procedures

The preference for minimally invasive procedures, such as Sialendoscopy, in the treatment of recurrent Parotitis has increased. These procedures offer less pain, shorter recovery time, and reduced risk of complications, driving their adoption in the market

Opportunities

• Increasing Research and Development

Continued research and development efforts focused on understanding the underlying causes of recurrent Parotitis and developing more effective treatment options can create opportunities for innovative therapies. This includes the exploration of new drug formulations, targeted therapies, and personalized medicine approaches.

• Increasing Technological Advancements

Advancements in medical technology, such as improved imaging techniques and minimally invasive procedures, can enhance the accuracy of diagnosis and effectiveness of treatment. This can create opportunities for the adoption of advanced treatment modalities.

Restraints/Challenges

• High Cost of Treatment

Certain treatment options for recurrent Parotitis, such as Sialendoscopy and surgical interventions, can be expensive. The high cost of these procedures may limit their accessibility, especially in regions with limited healthcare resources or patients with financial constraint.

• Lack of Standardized Treatment Guidelines

There is a lack of standardized treatment guidelines for recurrent Parotitis, leading to variations in treatment approaches among healthcare providers. This can result in inconsistent treatment outcomes and hinder market growth.

• Potential Complications and Adverse Effects

Some treatment options for recurrent Parotitis, such as surgical interventions, carry the risk of complications and adverse effects. This can lead to patient concerns and reluctance to undergo certain treatments, impacting market growth.

• Challenges in Drug Development

Developing new drugs specifically targeting recurrent Parotitis can be challenging due to the complex nature of the condition. Limited research and development in this area may result in a lack of effective pharmacological treatment options.

This global recurrent parotitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recurrent global parotitis treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In September 2021, Medtronic announced the launch of their new sialendoscopy product, the Medtronic SialoCath™ System, for the treatment of salivary gland disorders including recurrent parotitis. The system offers minimally invasive treatment options for patients
• In August 2021, Sonova Holding AG, a Swiss company specializing in hearing care solutions, announced a collaboration with the University of Zurich to develop a non-invasive treatment for recurrent parotitis using low-intensity focused ultrasound therapy
• In May 2021, Merck KGaA and Artios Pharma Limited announced a research collaboration to develop novel DNA damage response (DDR) targeted therapies for the treatment of various diseases, including recurrent parotitis. The collaboration aims to identify new treatment options based on DDR inhibitors
• In April 2021, Olympus Corporation, a global leader in medical technology, introduced their new EndoTherapy solutions for salivary gland disorders, including recurrent parotitis. The solutions include specialized devices for diagnosis and treatment

Global Recurrent Parotitis Treatment Market Scope

The global recurrent parotitis treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medications
• Antibiotics
• Analgesics
• Sialagogues
• Sialoendoscopy
• Parotidectomy
• Radiotherapy
• Tympanic Neurectomy
• Others
• Warm Compresses
• Others

 Diagnosis

• X-Ray
• Computed Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI)
• Sialography
• Ultrasonography
• Others

Symptoms

• Fever
• Inflammation of the Parotid Gland
• Redness
• Recurrence of Inflammation and Swelling in Repeated Episodes
• Pain
• Others

Dosage

• Injection
• Tablets
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Recurrent Parotitis Treatment Market Regional Analysis/Insights

The global parotitis treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global recurrent parotitis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the global recurrent parotitis treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having recurrent parotitis.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for treatment and diagnosis, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global recurrent parotitis treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global recurrent parotitis treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global recurrent parotitis treatment market. The data is available for the historic period 2015-2020

Competitive Landscape and Global Recurrent Parotitis Treatment Market Share Analysis

글로벌 재발성 이하선염 치료 시장 경쟁 구도는 경쟁업체의 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭 및 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 글로벌 재발성 이하선염 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 재발성 이하선염 치료 시장에서 활동하는 주요 업체는 다음과 같습니다.

• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• 사노피(프랑스)
• 애벗(미국)
• Bayer AG(독일)
• 브리스톨-마이어스 스퀴브 회사(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 마일런 NV(미국)
• 알러간(아일랜드)
• 머크앤코(미국)
• 멜린타 테라퓨틱스 LLC(미국)
• Basilea Pharmaceutica Ltd. (스위스)
• 테트라페이즈 파마슈티컬스(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도), 시오노기(일본)
• AbbVie Inc.(미국)
• 컴벌랜드 제약 주식회사(미국)
• 엘리 릴리 앤드 컴퍼니(미국)
• 베링거인겔하임인터내셔널(독일)
• 다케다제약 주식회사(일본)

SKU-67515